<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03956355</url>
  </required_header>
  <id_info>
    <org_study_id>DMVT-505-3001</org_study_id>
    <nct_id>NCT03956355</nct_id>
  </id_info>
  <brief_title>Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)</brief_title>
  <official_title>A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermavant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IQVIA Biotech</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dermavant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy&#xD;
      and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in&#xD;
      adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to&#xD;
      receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 12-week double-blind, vehicle-controlled treatment study in which subjects&#xD;
      will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 12 weeks.&#xD;
      At the end of the 12-week study treatment, qualified subjects completing the study will have&#xD;
      the option to enter a separate open-label, long-term safety and efficacy study for an&#xD;
      additional 40 weeks of treatment with tapinarof cream, 1%. Subjects who do not enroll in the&#xD;
      open-label long-term study will complete a follow-up visit approximately 4 weeks after end of&#xD;
      treatment in this study (at Week 16).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Actual">May 26, 2020</completion_date>
  <primary_completion_date type="Actual">May 26, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Following a 34-day screening period, eligible subjects will be randomized at a 2:1 ratio to receive once daily treatment with tapinarof cream, 1% or vehicle cream.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The Investigator, study center staff, subject, and Sponsor will be blinded to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve a Physician Global Assessment (PGA) score of clear (0) or almost clear (1) with a minimum 2-grade improvement from Baseline at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, scaling, and plaque thickness/elevation as guidelines. Higher PGA scores represent more severe disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ 75% improvement in Psoriasis Area and Severity Index (PASI) from Baseline at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The PASI scoring system is a widely-used standard clinical tool for assessing the severity of psoriasis that takes into account the overall severity of erythema (redness), induration (plaque thickness), and scale, and the extent of %Body Surface Area (BSA) affected with psoriasis. The 3 clinical signs are each graded on a 5-point scale (0 to 4) and the %BSA affected is scored on a 7-point scale (0 to 6) for each of the 4 specified body regions (head, upper extremities, trunk, and lower extremities). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a PGA score of 0 or 1 at Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, scaling, and plaque thickness/elevation as guidelines. Higher PGA scores represent more severe disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in percent of total body surface area (%BSA) affected from Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥90% improvement in PASI score from Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The PASI scoring system is a widely-used standard clinical tool for assessing the severity of psoriasis that takes into account the overall severity of erythema (redness), induration (plaque thickness), and scale, and the extent of %BSA affected with psoriasis. The 3 clinical signs are each graded on a 5-point scale (0 to 4) and the %BSA affected is scored on a 7-point scale (0 to 6) for each of the 4 specified body regions (head, upper extremities, trunk, and lower extremities). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">510</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Tapinarof (DMVT-505)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tapinarof (DMVT-505) Cream Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Cream Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tapinarof (DMVT-505)</intervention_name>
    <description>Tapinarof cream, 1%, applied once daily</description>
    <arm_group_label>Tapinarof (DMVT-505)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Cream</intervention_name>
    <description>Vehicle cream applied once daily</description>
    <arm_group_label>Vehicle Cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects ages 18 to 75 years with clinical diagnosis of chronic plaque&#xD;
             psoriasis and stable disease for at least 6 months prior to the study.&#xD;
&#xD;
          -  BSA involvement ≥ 3% and ≤ 20%&#xD;
&#xD;
          -  A PGA score of 2 (mild), 3 (moderate) or 4 (severe) at screening and baseline&#xD;
&#xD;
          -  Females of child bearing potential and male subjects who are engaging in sexual&#xD;
             activity that could lead to pregnancy agree to follow the specified contraceptive&#xD;
             guidance throughout the study, including screening, during the treatment period, and&#xD;
             for at least 4 weeks after the last exposure to study treatment&#xD;
&#xD;
          -  Capable of giving written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psoriasis other than plaque variant&#xD;
&#xD;
          -  Any sign of infection of any of the psoriatic lesions&#xD;
&#xD;
          -  Concurrent conditions or history of other diseases:&#xD;
&#xD;
          -  Immunocompromised at Screening&#xD;
&#xD;
          -  Chronic or acute infection requiring treatment with systemic antibiotics, antivirals,&#xD;
             antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to the Baseline&#xD;
             visit&#xD;
&#xD;
          -  Acute active bacterial, fungal, or viral (herpes simplex, herpes zoster, chicken pox)&#xD;
             skin infection within 1 week prior to the Baseline visit&#xD;
&#xD;
          -  Significant dermatologic or inflammatory condition other than plaque psoriasis that,&#xD;
             in the Investigator's opinion, would make it difficult to interpret data or&#xD;
             assessments during the study&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5x the upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 x ULN; total bilirubin &gt; ULN and ≤ 1.5 x ULN is acceptable if&#xD;
             bilirubin is fractionated and direct bilirubin &lt; 35%&#xD;
&#xD;
          -  Corrected QT interval &gt; 475&#xD;
&#xD;
          -  Current or chronic history of liver disease, known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones), presence of&#xD;
             hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test result, or&#xD;
             a positive anti-hepatitis B core antigen (anti-HBc) result&#xD;
&#xD;
          -  Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources&#xD;
             of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such&#xD;
             exposures during the study which could potentially impact the subject's psoriasis&#xD;
&#xD;
          -  Use of any prohibited medication within the indicated period before the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Within a minimum of 5 half-lives for biologic agents:&#xD;
&#xD;
          -  Within 4 weeks for systemic immunosuppressive or immunomodulating agents, fumaric acid&#xD;
             derivatives, vitamin D3 and analogs, retinoids, psoralens, corticosteroids,&#xD;
             adrenocorticotropic hormone analogs, and tazarotene&#xD;
&#xD;
          -  2 weeks for immunizations with a live viral component; drugs known to possibly worsen&#xD;
             psoriasis, unless on a stable dose for &gt; 12 weeks&#xD;
&#xD;
          -  With the exception of non-medicated emollients, 2 weeks for topical treatments&#xD;
             including corticosteroids, immunomodulators, anthralin (dithranol), vitamin D&#xD;
             derivatives or coal tar.&#xD;
&#xD;
          -  Pregnant females or lactating females&#xD;
&#xD;
          -  History of sensitivity to the study drugs, or components thereof or a history of drug&#xD;
             or other allergy that, in the opinion of the Investigator or Medical Monitor,&#xD;
             contraindicates the subject's participation in the study&#xD;
&#xD;
          -  The subject has received an investigational product within 30 days, 5 half-lives, or&#xD;
             twice the duration of the biological effect of the study drug (whichever is longer)&#xD;
             prior to first dose of study drug&#xD;
&#xD;
          -  Current or a history of cancer within 5 years except for fully excised skin basal cell&#xD;
             carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Subjects with active infection that required oral, intramuscular, or intravenous&#xD;
             administration of antibiotics, antifungal or antiviral agents within 7 days of&#xD;
             Baseline/Day 1&#xD;
&#xD;
          -  Previous known participation in a clinical study with tapinarof&#xD;
&#xD;
          -  Evidence of significant hepatic, renal, respiratory, endocrine, hematologic,&#xD;
             neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory&#xD;
             abnormality that will affect the health of the subject or interfere with&#xD;
             interpretation of the results&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria Butners</last_name>
    <role>Study Director</role>
    <affiliation>Dermavant Sciences GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Anaheim Hills</city>
        <state>California</state>
        <zip>92807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Cromwell</city>
        <state>Connecticut</state>
        <zip>06416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Kew Gardens</city>
        <state>New York</state>
        <zip>11374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <zip>02919</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Dripping Springs</city>
        <state>Texas</state>
        <zip>78620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Saint Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 2H5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 7K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Coburg</city>
        <state>Ontario</state>
        <zip>K9A 0Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Richmond Hill</city>
        <state>Ontario</state>
        <zip>L4C 9M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3H 5Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermavant Investigative Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 2V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology. 2015;230(1):27-33. doi: 10.1159/000365390. Epub 2015 Jan 20.</citation>
    <PMID>25613671</PMID>
  </results_reference>
  <results_reference>
    <citation>Lebwohl M, Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2014 Jun;53(6):714-22. doi: 10.1111/j.1365-4632.2012.05798.x. Epub 2013 Apr 4.</citation>
    <PMID>23557000</PMID>
  </results_reference>
  <results_reference>
    <citation>Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD005028. doi: 10.1002/14651858.CD005028.pub3. Review.</citation>
    <PMID>23543539</PMID>
  </results_reference>
  <results_reference>
    <citation>Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377-85. doi: 10.1038/jid.2012.339. Epub 2012 Sep 27. Review.</citation>
    <PMID>23014338</PMID>
  </results_reference>
  <results_reference>
    <citation>Strober BE, Nyirady J, Mallya UG, Guettner A, Papavassilis C, Gottlieb AB, Elewski BE, Turner-Bowker DM, Shields AL, Gwaltney CJ, Lebwohl M. Item-level psychometric properties for a new patient-reported psoriasis symptom diary. Value Health. 2013 Sep-Oct;16(6):1014-22. doi: 10.1016/j.jval.2013.07.002.</citation>
    <PMID>24041351</PMID>
  </results_reference>
  <results_reference>
    <citation>Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nyirady J, Papavassilis C, Nelson LM, McLeod LD, Mordin M, Gottlieb AB, Elewski BE, Lebwohl M. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. Int J Dermatol. 2016 Mar;55(3):e147-55. doi: 10.1111/ijd.13117. Epub 2015 Oct 30.</citation>
    <PMID>26518255</PMID>
  </results_reference>
  <results_reference>
    <citation>Zoetis T, Hurtt ME. Species comparison of anatomical and functional renal development. Birth Defects Res B Dev Reprod Toxicol. 2003 Apr;68(2):111-20. Review.</citation>
    <PMID>12866702</PMID>
  </results_reference>
  <results_reference>
    <citation>Cappon GD and Hurtt ME. Developmental toxicity of the kidney. In: Kapp RW and Yyl L, editors. Reproductive Toxicology, Target Organ Series, 3rd edition. New York:Informa Healthcare, 2010:193-204.</citation>
  </results_reference>
  <results_reference>
    <citation>Frazier KS and Seely JC. Urinary system. In: Sahota PS, Popp JA, Hardisty JF and Gopinath C, editors. Toxicologic Pathology: Nonclinical Safety Assessment. CRC Press, 2013:421-84.</citation>
  </results_reference>
  <results_reference>
    <citation>Maruish, ME, editor. User's manual for the SF-36v2 health survey. Edition 3. Quality Metric Inc. 2011.</citation>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2019</study_first_posted>
  <disposition_first_submitted>October 7, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>October 7, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 19, 2020</disposition_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tapinarof</keyword>
  <keyword>plaque psoriasis</keyword>
  <keyword>adult</keyword>
  <keyword>phase 3</keyword>
  <keyword>topical</keyword>
  <keyword>double-blind</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

